On this page

Ciclopirox Olamine

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Ciclopirox Olamine
Generic name
Ciclopirox Olamine
Dosage form
Suspension
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
6
Packages
8
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Ciclopirox Olamine 7.7 mg/100mL 309290 View
Ciclopirox Olamine 7.7 mg/mL 309290 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Suspension
Route of administration
Topical
Presentations
14

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Decreased DNA Replication [PE] PE 5 members — no class page
Decreased Protein Synthesis [PE] PE 7 members — no class page
Decreased RNA Replication [PE] PE 5 members — no class page
Protein Synthesis Inhibitors [MoA] MoA 7 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
077676
Application type
ANDA · Abbreviated New Drug Application
Approval date
December 15, 2006
Sponsor
PADAGIS ISRAEL
Products on application
1
Submissions recorded
2
Products approved under application 077676.
Product Trade name Form Strength Ingredient Status TE Flags
077676-001 CICLOPIROX SUSPENSION CICLOPIROX Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 077676.
Type No. Action Status Date Review
Supplement 12 Labeling Approved April 10, 2025 Standard
Original application 1 Approved December 15, 2006 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260416). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260416 HUMAN PRESCRIPTION DRUG · 20241224

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur .

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Gently massage Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS General - Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is not for ophthalmic use. Keep out of reach of children.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In the controlled clinical trial with 89 patients using ciclopirox olamine topical suspension and 89 patients using the vehicle, the incidence of adverse reactions was low. Those considered possibly related to treatment or occurring in more than one patient were pruritus, which occurred in two patients using ciclopirox olamine topical suspension and one patient using the suspension vehicle, and burning, which occurred in one patient using ciclopirox olamine topical suspension. To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is for topical use. Each gram of Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) contains 7.70 mg of ciclopirox (as ciclopirox olamine) in a water miscible suspension base consisting of benzyl alcohol (1% as a preservative), cetyl alcohol, lactic acid, light mineral oil, myristyl alcohol, octyldodecanol, polysorbate 60, purified water, sorbitan monostearate, and stearyl alcohol. Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )-pyridone, 2-aminoethanol salt. The CAS Registry Number is 41621-49-2. Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) has a pH of 7. The chemical structure is:

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is available as follow: NDC: 72162-1406-3: 30 mL in a BOTTLE NDC: 72162-1406-6: 60 mL in a BOTTLE Bottle space provided to allow for vigorous shaking before each use. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Adverse event reports

Source: openFDA FAERS
470
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CICLOPIROX OLAMINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-2522-1 63629-2522 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (63629-2522-1) / 30 mL in 1 BOTTLE December 29, 2006
63629-8627-1 63629-8627 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (63629-8627-1) / 60 mL in 1 BOTTLE December 29, 2006
71335-2717-1 71335-2717 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (71335-2717-1) / 60 mL in 1 BOTTLE July 28, 2025
71335-2915-1 71335-2915 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (71335-2915-1) / 30 mL in 1 BOTTLE October 24, 2025
72162-1406-3 72162-1406 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (72162-1406-3) / 30 mL in 1 BOTTLE October 2, 2023
72162-1406-6 72162-1406 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (72162-1406-6) / 60 mL in 1 BOTTLE October 2, 2023
45802-400-46 45802-400 Padagis Israel Pharmaceuticals Ltd 1 BOTTLE in 1 CARTON (45802-400-46) / 60 mL in 1 BOTTLE December 29, 2006
45802-400-49 45802-400 Padagis Israel Pharmaceuticals Ltd 1 BOTTLE in 1 CARTON (45802-400-49) / 30 mL in 1 BOTTLE December 29, 2006
63629-2522 63629-2522 Bryant Ranch Prepack — December 29, 2006
63629-8627 63629-8627 Bryant Ranch Prepack — December 29, 2006
71335-2717 71335-2717 Bryant Ranch Prepack — December 29, 2006
71335-2915 71335-2915 Bryant Ranch Prepack — December 29, 2006
72162-1406 72162-1406 Bryant Ranch Prepack — December 29, 2006
45802-400 45802-400 Padagis Israel Pharmaceuticals Ltd — December 29, 2006

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.